Sol-Gel Technologies Ltd.

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Delayed Nasdaq 03:16:52 2024-04-25 pm EDT 5-day change 1st Jan Change
0.8954 USD -2.67% Intraday chart for Sol-Gel Technologies Ltd. -0.51% -18.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director CI
Transcript : Sol-Gel Technologies Ltd. - Special Call
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study CI
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board CI
HC Wainwright Cuts Sol-Gel Technologies' Price Target to $9 From $12, Keeps Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Sol-Gel Technologies to $12 From $19, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $7 From $9, Maintains Strong Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sol-Gel Technologies Ltd. Appoints Sharon Kochan to the Board of Directors CI
Raymond James Adjusts Sol-Gel Technologies' Price Target to $9 From $10, Keeps Strong Buy Rating MT
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs MT
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sol-Gel Technologies Ltd. announced that it has received $10 million in funding from M. Arkin Dermatology Ltd. CI
Raymond James Adjusts Price Target on Sol-Gel Technologies to $10 From $13, Maintains Strong Buy Rating MT
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Transcript : Sol-Gel Technologies Ltd. - Special Call
Sol-Gel Technologies Launches $22.8 Million Registered Direct, Private Placement Offerings; Shares Drop Pre-Bell MT
Sol-Gel Technologies Ltd. announced that it expects to receive $10 million in funding from M. Arkin Dermatology Ltd. CI
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
HC Wainwright Cuts Price Target on Sol-Gel Technologies to $19 From $22, Affirms Buy Rating MT
Raymond James Adjusts Price Target on Sol-Gel Technologies to $13 From $16, Maintains Strong Buy Rating MT
Chart Sol-Gel Technologies Ltd.
More charts
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.92 USD
Average target price
8 USD
Spread / Average Target
+769.57%
Consensus
  1. Stock Market
  2. Equities
  3. SLGL Stock
  4. News Sol-Gel Technologies Ltd.
  5. Sol Gel Technologies : FDA Accepts Sol-Gel Technologies' New Drug Application For Acne Cream Drug Candidate